A significant difference was observed in CD103+CD8+ TRMs infiltrating the tumor compared to the peripheral blood CD8+ T cell group, and the killing ability of the CD103+CD8+ TRMs treatment group was greater (Fig. 4D–F). This evidence concerns the gene CD8A and neoplasm.